State of Wyoming Purchases Shares of 23,244 Kodiak Sciences Inc. $KOD

State of Wyoming purchased a new position in Kodiak Sciences Inc. (NASDAQ:KOD) in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 23,244 shares of the company’s stock, valued at approximately $906,000.

Several other institutional investors have also recently made changes to their positions in KOD. V Square Quantitative Management LLC bought a new position in shares of Kodiak Sciences during the 1st quarter valued at approximately $26,000. Westfuller Advisors LLC purchased a new stake in Kodiak Sciences in the 1st quarter worth approximately $26,000. EverSource Wealth Advisors LLC raised its stake in Kodiak Sciences by 1,221.3% during the 4th quarter. EverSource Wealth Advisors LLC now owns 991 shares of the company’s stock worth $28,000 after acquiring an additional 916 shares during the period. GF Fund Management CO. LTD. bought a new stake in Kodiak Sciences during the 4th quarter worth approximately $29,000. Finally, Headlands Technologies LLC lifted its holdings in Kodiak Sciences by 256.4% during the second quarter. Headlands Technologies LLC now owns 8,083 shares of the company’s stock valued at $30,000 after purchasing an additional 5,815 shares in the last quarter. Institutional investors own 89.06% of the company’s stock.

Kodiak Sciences Trading Up 3.4%

Shares of KOD opened at $41.35 on Friday. The business’s 50 day moving average is $39.10 and its 200 day moving average is $34.95. The company has a market capitalization of $2.59 billion, a PE ratio of -9.87 and a beta of 2.21. Kodiak Sciences Inc. has a 12-month low of $8.29 and a 12-month high of $47.84.

Kodiak Sciences (NASDAQ:KOD) last posted its quarterly earnings results on Wednesday, August 12th. The company reported ($1.05) earnings per share for the quarter, missing the consensus estimate of ($0.96) by ($0.09). Equities research analysts predict that Kodiak Sciences Inc. will post -3.74 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of research firms have weighed in on KOD. Chardan Capital upgraded shares of Kodiak Sciences from a “neutral” rating to a “buy” rating and upped their price target for the stock from $14.00 to $61.00 in a research report on Monday, May 11th. Wall Street Zen downgraded shares of Kodiak Sciences from a “hold” rating to a “sell” rating in a research report on Saturday. Weiss Ratings restated a “sell (d-)” rating on shares of Kodiak Sciences in a research note on Friday, July 10th. Finally, JPMorgan Chase & Co. upped their target price on shares of Kodiak Sciences from $56.00 to $66.00 and gave the stock an “overweight” rating in a report on Monday, August 3rd. Six analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, Kodiak Sciences presently has a consensus rating of “Moderate Buy” and a consensus target price of $48.14.

Kodiak Sciences Profile

Kodiak Sciences, Inc is a clinical‐stage biopharmaceutical company headquartered in Palo Alto, California, that focuses on the discovery and development of novel therapies for retinal diseases. The company’s proprietary technology centers on antibody biopolymer conjugates (ABCs), which are designed to extend durability, enhance tissue penetration and improve the safety profile of existing therapeutic modalities. Kodiak’s research and development efforts target conditions such as wet age-related macular degeneration (wet AMD), diabetic macular edema (DME) and other serious ophthalmic disorders.

The lead product candidate in Kodiak’s pipeline is KSI-301, an anti-VEGF antibody biopolymer conjugate administered via intravitreal injection.